Apadaz was initially approved in February 2018 as 6.12mg/325mg immediate-release tablets for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Approximately half of patients with migraine have kinesiophobia, and the condition is associated with greater severity, not presence of cutaneous allodynia.
Chronic opioid use during pregnancy that causes neonatal abstinence syndrome is associated with smaller neonatal head circumference.
An ultrarestrictive opioid prescription protocol can reduce the number of opioids prescribed to patients after gynecologic and abdominal surgery without negative health consequences.
Military patients whose primary care clinicians participated in a telementoring program have larger declines in opioid-related prescriptions than patients whose clinicians did not participate.
The FDA has issued a safety communication regarding the risks associated with implanted pumps for intrathecal administration of pain medications.
The quantity of opioids prescribed after surgery is associated with patient-reported opioid consumption.
The number of opioid overdose deaths in the United States reached a new record last year with 72,000 deaths, which works out to about 200 a day.
Ruling against the recommendation of one of its chief experts, the US FDA approved an extremely potent new opioid painkiller, Dsuvia.
Many patients in a workers' compensation cohort have persistent opioid use.
A "Pain and Stress Management" program for the management of chronic pain, was found to be effective in alleviating pain, diminishing stress, promoting self-management of pain, and ameliorating general well-being.
A bipartisan bill meant to combat the United States' opioid abuse epidemic was signed into law October 24 by President Donald Trump.
Dorsal root ganglion neurostimulation therapy may reduce pain and disability in patients with chronic lower extremity and back pain.
The FDA is not bound by the Committee's recommendation but takes it into consideration when making its decision.
Receiving prescriptions from both the US Department of Veterans Affairs and Medicare Part D is associated with increased risk for overlapping of opioid and benzodiazepine prescriptions.
A bipartisan bill to fight the opioid addiction crisis in the United States has been passed by Congress.
An "enhanced recovery after surgery" program is associated with a significant reduction in opioid consumption after gynecologic surgery with no increase in pain scores.
In a rare bipartisan move, both the House and Senate have reached a compromise on legislation to address the opioid epidemic.
Potentially inappropriate prescribing (PIP) of opioids is associated with increased risk of all-cause mortality and fatal and nonfatal overdose.
As part of the REMS program, drug companies with approved opioid analgesics must make training available to prescribers and provide unrestricted grants to accredited continuing education providers for the development of education courses.
About 20.4% of US adults have chronic pain and 8.0% have high-impact chronic pain.
Many outpatient opioid prescriptions have no documented medical indication.
Chronic pain may be an important contributor to suicide, with 8.8 percent of suicide decedents having evidence of chronic pain.
Purdue Pharma, the maker of Oxycontin who some have blamed for the epidemic of opioid painkiller addictions, has patented a medicine aimed at curbing those disorders.
Among surgical patients who develop new persistent opioid use, surgeons provide the majority of opioid prescriptions in the first few months after surgery.
A $3.4 million grant to help a non-profit company develop a less expensive opioid overdose antidote was announced by Purdue Pharma, which makes the opioid painkiller OxyContin.
The new plan will break out the current guidance into 4 separate guidances.
Rates of opioid use in the United States do not appear to be declining.
Four more online networks that operate 21 websites illegally selling potentially dangerous, unapproved, and misbranded versions of opioid pain medications have been told to immediately stop their sales.
Concomitant exposure to pregabalin and opioids is associated with increased odds of opioid-related death.
Neurology Advisor Articles
- Survival in Parkinson Disease Dependent on Parkinsonian Type, Characteristics
- Case Study Report: Herbal Supplement Kratom Associated With Neonatal Abstinence Syndrome
- Mobile Health Apps for Headache: An Ongoing Search for Clinical Relevancy
- Young Fresh Frozen Plasma Infusion Safe, Feasible in Alzheimer Disease
- Behavioral Therapies May Treat Headache and Post-Concussive Symptoms
- Alemtuzumab Linked to Clinical and MRI Disease Remission in Multiple Sclerosis
- Very Early Mobilization After Stroke Does Not Improve Survival Over Usual Care
- Cognitive Decline Worsens With Memantine, ChEIs in Patients With Alzheimer's
- Levodopa Inhalation Powder Approved for Parkinson Disease
- Hematology Indicates Need for Thrombophilia Test in Children With Migraines
- Can Early Initiation of Direct Oral Anticoagulants Prevent Recurrent AFib-Related Stroke?
- Hydrocephalus May Be a Complication of Congenial Zika Syndrome
- Higher CSF NfL Protein Levels Linked to Risk for Mild Cognitive Impairment
- Addressing Cognitive Impairment in Pediatric MS: Expert Q&A
- How the Government Shutdown Affects FDA Activities